Mifepristone (RU486): Progesterone Receptor Antagonist for Cancer and Reproductive Biology Research

Executive Summary: Mifepristone (RU486) is a high-affinity antagonist of the progesterone receptor, validated for cancer and reproductive biology research (https://www.apexbt.com/mifepristone.html). It inhibits the proliferation of ovarian, breast, prostate, and gastric adenocarcinoma cell lines with measurable IC₅₀ values under defined conditions. The compound modulates human sperm function by blocking the progesterone-induced acrosome reaction and intracellular calcium flux. It demonstrates efficacy in reducing uterine fibroid size and meningioma growth in both in vitro and in vivo models. Mifepristone’s mechanism involves downregulation of cell cycle cyclins, resulting in cell cycle arrest and tumor growth inhibition (Li et al., 2018).

Biological Rationale

Mifepristone (RU486) is a synthetic steroid that competitively antagonizes the progesterone receptor (PR), a nuclear hormone receptor essential for reproductive tissue maintenance and hormone-responsive tumor growth (APExBIO). PR signaling regulates gene expression in endometrial, ovarian, and breast tissues. Aberrant PR activity is implicated in tumorigenesis, endometrial hyperplasia, and uterine fibroids. By inhibiting PR, Mifepristone enables precise dissection of hormone-dependent biological processes and facilitates the evaluation of PR-targeted therapies in preclinical models. Its established use in cell viability, proliferation, and hormone response assays is detailed in scenario-driven protocols (Scenario-Driven Solutions with Mifepristone (RU486)), extending previous workflow-focused articles by integrating updated mechanistic insights.

Mechanism of Action of Mifepristone (RU486)

Mifepristone exerts its primary effect by binding the progesterone receptor with high affinity, preventing endogenous progesterone from activating downstream gene expression. This antagonism results in the modulation of reproductive tissue differentiation and suppression of hormone-responsive cell proliferation. The compound also displays antagonistic activity at the glucocorticoid receptor at higher concentrations, expanding its utility in studies of steroid hormone signaling ( Li et al., 2018). In ovarian cancer cell lines, Mifepristone induces dose-dependent growth inhibition, with IC₅₀ values of 6.25 μmol/L for SK-OV-3 and 6.91 μmol/L for OV2008 cells under standard culture conditions (37°C, 5% CO₂, 48–72 h exposure). It suppresses the S-phase and M-phase cyclins (A and B1), resulting in cell cycle arrest. In sperm studies, Mifepristone inhibits progesterone-induced acrosome reaction, hyperactivation, and intracellular calcium elevation, indicating a direct effect on gamete function (Advanced Protocols for Cancer and Reproductive Biology offers practical extensions for these findings).

Evidence & Benchmarks

• Mifepristone inhibits SK-OV-3 and OV2008 ovarian cancer cell growth with IC₅₀ values of 6.25 μmol/L and 6.91 μmol/L, respectively, under in vitro conditions (Xu et al., 2011, PubMed).
• Reduces uterine fibroid size and volume in preclinical models after repeated administration (Tang et al., 2017, DOI).
• Suppresses meningioma growth both in vitro and in vivo, associated with PR antagonism (Grunberg et al., 2006, PubMed).
• Inhibits the progesterone-induced acrosome reaction, hyperactivation, and intracellular Ca²⁺ influx in human sperm at 10 μmol/L (Liu et al., 1996, PubMed).
• Reduces cyclin A and B1 expression in ovarian cancer cells, leading to cell cycle arrest (Goyeneche et al., 2007, PubMed).
• Demonstrates dose-dependent tumor growth inhibition in xenograft models using T47D and A549 cell lines (Li et al., 2018, DOI).

Applications, Limits & Misconceptions

Mifepristone (RU486) is routinely used as a tool compound in oncology, reproductive biology, and hormone signaling research. It is particularly valuable for mechanistic studies of PR signaling and as a benchmark for evaluating new antagonists. The compound also serves as a positive control in cell cycle, apoptosis, and receptor binding assays. APExBIO's formulation (B1511) offers high solubility (≥21.48 mg/mL in DMSO and ethanol) but is insoluble in water. For long-term stability, stock solutions should be stored at or below -20°C and used within several months. See the B1511 kit for detailed handling protocols.

This article augments prior work on cell-permeable progesterone receptor antagonists by providing updated quantitative benchmarks and clarifying the range of validated applications.

Common Pitfalls or Misconceptions

• Mifepristone is not a selective glucocorticoid receptor antagonist; GR antagonism occurs only at significantly higher concentrations than PR antagonism.
• The compound is not effective in water-based buffers due to insolubility; DMSO or ethanol is required for stock preparation.
• Long-term storage of diluted solutions at room temperature leads to loss of potency; always store below -20°C.
• In vivo efficacy may vary across tumor models; benchmarks are primarily established in breast, ovarian, and meningioma models.
• Does not reverse androgen receptor–mediated resistance in prostate cancer; AR heterogeneity requires alternative targeting (Li et al., 2018, DOI).

Workflow Integration & Parameters

Mifepristone (RU486) is supplied as a solid and is soluble at ≥21.48 mg/mL in DMSO or ethanol with gentle warming. Prepare fresh working solutions prior to each experiment. For cell culture assays, use concentrations ranging from 1–10 μmol/L depending on cell type and endpoint. Stock solutions can be stored at -20°C for several months; avoid repeated freeze-thaw cycles. For tumor xenograft studies, dosing regimens should be optimized based on in vivo pharmacokinetics and tumor type. Shipping from APExBIO is performed on blue ice for small molecule stability.

For advanced integration strategies, see Precision Targeting of Progesterone Receptors, which focuses on translational research and combinatorial workflows; this article builds on that by including specific solubility and storage parameters for laboratory reproducibility.

Conclusion & Outlook

Mifepristone (RU486) is a benchmark progesterone receptor antagonist validated for robust, reproducible research in oncology and reproductive biology. Its well-characterized mechanism, defined solubility profile, and extensive preclinical evidence make it a reference standard for hormone receptor signaling studies. APExBIO’s formulation (SKU B1511) ensures high purity and workflow compatibility. Future directions include the use of Mifepristone in combination regimens and as a model for developing next-generation receptor antagonists.